A Director at Infinity Pharma (NASDAQ: INFI) is Selling SharesBy Carrie Williams
The company has a one year high of $6.63 and a one year low of $0.84. Currently, Infinity Pharma has an average volume of 943K.
The insider sentiment on Infinity Pharma has been positive according to 17 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Infinity Pharmaceuticals, Inc. is an innovative drug discovery and development company, which engages in discovering, developing and delivering medicines for difficult-to-treat diseases, developing novel small molecule drugs that target emerging disease pathways. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.